Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection

被引:171
|
作者
Kashiwakura, Y
Tamayose, K
Iwabuchi, K
Hirai, Y
Shimada, T
Matsumoto, K
Nakamura, T
Watanabe, M
Oshimi, K
Daida, H
机构
[1] Juntendo Univ, Sch Med, Dept Hematol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Juntendo Univ, Sch Med, Dept Cardiol, Tokyo, Japan
[3] Nippon Med Coll, Dept Biochem & Mol Biol, Tokyo, Japan
[4] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Chiba, Japan
[5] Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Osaka, Japan
[6] Okayama Univ, Grad Sch Med & Dent, Dept Urol, Okayama, Japan
关键词
D O I
10.1128/JVI.79.1.609-614.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
After the first attachment of virus to the cell surface through a primary receptor, efficient entry of virus requires the presence of a coreceptor. For adeno-associated virus type 2 (AAV2) infection, heparan sulfate proteoglycan is supposed as the primary receptor, and alphavbeta5 integrin and FGFR1 are reported to act as coreceptors. In this study, we were able to demonstrate that hepatocyte growth factor receptor, e-Met, is also a coreceptor for AAV2 infection. AAV2-mediated transgene analyses revealed that c-Met expression significantly up-regulated transgene expression without increasing AAV2 cell binding. Moreover, a viral overlay assay elucidated the physical interaction between AAV2 and the beta subunit of c-Met. These data suggest that c-Met plays the role of coreceptor for AAV2 infection by facilitating AAV2 internalization into the cytoplasm.
引用
收藏
页码:609 / 614
页数:6
相关论文
共 50 条
  • [21] Infection of purified nuclei by adeno-associated virus 2
    Hansen, J
    Qing, K
    Srivastava, A
    MOLECULAR THERAPY, 2001, 4 (04) : 289 - 296
  • [22] GENETICS OF ADENO-ASSOCIATED VIRUS - ISOLATION AND PRELIMINARY CHARACTERIZATION OF ADENO-ASSOCIATED VIRUS TYPE-2 MUTANTS
    HERMONAT, PL
    LABOW, MA
    WRIGHT, R
    BERNS, KI
    MUZYCZKA, N
    JOURNAL OF VIROLOGY, 1984, 51 (02) : 329 - 339
  • [23] Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
    Berns, Kenneth I.
    Byrne, Barry J.
    Flotte, Terence R.
    Gao, Guangping
    Hauswirth, William W.
    Herzog, Roland W.
    Muzyczka, Nicholas
    VandenDriessche, Thierry
    Xiao, Xiao
    Zolotukhin, Sergei
    Srivastava, Arun
    HUMAN GENE THERAPY, 2015, 26 (12) : 779 - 781
  • [24] Expression profiles of bovine adeno-associated virus and avian adeno-associated virus display significant similarity to that of adeno-associated virus type 5
    Qiu, Jianming
    Cheng, Fang
    Pintel, David J.
    JOURNAL OF VIROLOGY, 2006, 80 (11) : 5482 - 5493
  • [25] Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice
    Kazuhiro Suzumura
    Tadamichi Hirano
    Gakuhei Son
    Yuji Iimuro
    Hiroaki Mizukami
    Keiya Ozawa
    Jiro Fujimoto
    Hepatology International, 2008, 2 : 80 - 88
  • [26] Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice
    Suzumura, Kazuhiro
    Hirano, Tadamichi
    Son, Gakuhei
    Iimuro, Yuji
    Mizukami, Hiroaki
    Ozawa, Keiya
    Fujimoto, Jiro
    HEPATOLOGY INTERNATIONAL, 2008, 2 (01) : 80 - 88
  • [27] Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction
    Pilz, Ingo H.
    Di Pasquale, Giovanni
    Rzadzinska, Agnieszka
    Leppla, Stephen H.
    Chiorini, John A.
    VIROLOGY, 2012, 428 (01) : 58 - 63
  • [28] Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2
    Duverger, V
    Sartorius, U
    Klein-Bauernschmitt, P
    Krammer, PH
    Schlehofer, JR
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) : 706 - 712
  • [29] Receptor targeting of adeno-associated virus vectors
    Büning, H
    Ried, MU
    Perabo, L
    Gerner, FM
    Huttner, NA
    Enssle, J
    Hallek, M
    GENE THERAPY, 2003, 10 (14) : 1142 - 1151
  • [30] Receptor targeting of adeno-associated virus vectors
    H Büning
    M U Ried
    L Perabo
    F M Gerner
    N A Huttner
    J Enssle
    M Hallek
    Gene Therapy, 2003, 10 : 1142 - 1151